View:
United States securities and exchange commission logo
May 24, 2024
Troy Ignelzi
Chief Financial Officer
Rapport Therapeutics, Inc.
1325 Boylston Street, Suite 401
Boston, MA 02215
Re: Rapport
Therapeutics, Inc.
Registration
Statement on Form S-1
Filed May 17, 2024
File No. 333-279486
Dear Troy Ignelzi:
We have reviewed your
registration statement and have the following comment.
Please respond to this letter by amending your registration
statement and providing the
requested information. If you do not believe a comment applies to your
facts and circumstances
or do not believe an amendment is appropriate, please tell us why in
your response.
After reviewing any amendment to your registration statement and
the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form S-1 filed May 17, 2024
Risks Associated With Our Business, page 7
1. We note your revised
disclosure at the bottom of page 29 in response to prior comment 1.
Please add a new
Summary risk factor bullet point that highlights this specific risk.
We remind you that the company and its management are
responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration.
Please allow adequate
time for us to review any amendment prior to the requested effective
date of the registration
statement.
Troy Ignelzi
Rapport Therapeutics, Inc.
May 24, 2024
Page 2
Please contact Jenn Do at 202-551-3743 or Daniel Gordon at 202-551-3486
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Tamika Sheppard at 202-551-8346 or Joe McCann at 202-551-6262 with any other
questions.
Sincerely,
FirstName LastNameTroy Ignelzi
Division of
Corporation Finance
Comapany NameRapport Therapeutics, Inc.
Office of Life
Sciences
May 24, 2024 Page 2
cc: Justin Platt
FirstName LastName